Get In Touch with ViAn Therapeutics
Please tell us a little bit about yourself and why you'd like to get connected. ViAn Therapeutics + SOSV will follow up with you via email.
VIAN Therapeutics develops VIAN-001, a simple daily anti-angiogenic and anti-inflammatory eye drop for retinal diseases like AMD and DME. Designed to selectively target angiogenic endothelial cells, it inhibits angiogenesis and vascular permeability while reducing pro-inflammatory cytokines. Its topically active formulation delivers exceptional ocular penetration and longevity to help protect sight without invasive intravitreal injections.
The current $12B market for anti-VEGF in the eye is leaving half the market ($10B) on the table because up to 50% don’t respond to the current standard of care
Discovery and therapeutic targeting of new angiogenesis mediators is absolutely necessary to improve treatment of blinding eye diseases.
Please tell us a little bit about yourself and why you'd like to get connected. ViAn Therapeutics + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.